A new study shows that coating neural prosthetic implants with the anti-inflammatory drug dexamethasone helps reduce the body’s immune response and scar tissue formation.

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

An international research team, including scientists from the Institut de Neurociències at the Universitat Autònoma de ...

On the left, implant without dexamethasone; on the right, with treatment. As observed, the drug reduces the size of the fibrous capsule that forms around the implant after its surgical insertion into ...

Subcutaneous isatuximab administered via an on-body injector appears to be as safe and effective as intravenous isatuximab in patients with relapsed or refractory multiple myeloma.

Patients with subacute subdural hematoma (sASDH) do not have an optimal non-surgical therapeutic strategy. In this study, ...

Sanofi earns CHMP backing to expand Sarclisa's use for newly diagnosed multiple myeloma patients eligible for transplant.

On June 13, 2025, the UK National Institute for Health and Care Excellence (NICE) issued draft guidance recommending the use of belantamab mafodotin as a second-line treatment for multiple myeloma.

Dexamethasone belongs to a drug class called corticosteroids, or steroids. Dexamethasone is available in several brand-name versions, including Hemady, Dexabliss, and TaperDex.

Dexamethasone is approved to treat children ages 1 month and older, depending on the specific condition. The dosage for children is based on the child’s body weight in kilograms (kg).

Dexamethasone also comes in forms that are injectable and topical, but this article does not cover them. Read on to learn about potential common, mild, and serious side effects of dexamethasone.

To evaluate if an alternative, dexamethasone-sparing approach could improve outcomes while limiting toxicity for older adults, Manier and his colleagues conducted the prospective, open-label phase ...